Archives: Agenda

Cybersecurity in Financial Services: What Does the 2026 Landscape Look Like?

This forward-looking session explores how cybersecurity in financial services will evolve over the next 12–18 months. Drawing on GlobalData’s latest research, it will examine: 

  • The adoption and security implications of emerging technologies – including cloud, AI, 5G, IoT, and quantum computing.
  • How evolving business models and ecosystems in banking and financial services are reshaping cyber risk.
  • The balance between innovation, risk, and operational resilience in an increasingly complex digital environment.

Are you listening? How to retain, not just engage, stakeholders in clinical trials and people as partners

  • Effective communication with target patients/families/care professionals and RETAINING them
  • How inclusion of AI looks like in this communication, trust building, meeting needs and retaining engagement, from:
  • Care researchers’ perspective
  • Care Professionals’ perspective, and most importantly,
  • Caregivers’ perspective (lived experience and real-world-evidence) in the context of “rare diseases”

Artificial intelligence: what opportunities are there to incorporate this into temperature controlled logistics?

  • How can tools such as Chat GPT be applied to temperature controlled logistics in pharma supply chains?
  • Using data driven technologies such as AI to streamline operations and increase efficiency
  • Real life examples: where is AI being used in temperature sensitive supply chains outside of the industry and how can this be applied to pharma?
  • Exploring the potential of AI as a tool to improve biopharma supply chain logistics

CLOSING PANEL DISCUSSION: How AI is powering a new era of cancer drug discovery and development

  • Moving from basic functionalities to more meaningful impact and examples of this in practice
  • When AI is progressing so quickly, how will regulation evolve to match this speed?
  • When is AI not the answer?
  • How AI has revolutionised innovative ways of collecting data, biosimulation, and early disease diagnosis for oncology trials

Moderator: Asiyah Nawab, Senior Healthcare Analyst (Immunology Team), GlobalData

THIS SESSION WILL BE IN THE ONCOLOGY CONFERENCE ROOM

Clinical trials in rare immunology disorders

  • Overview of rare diseases in Immunology
  • Pharma focus on rare diseases in Immunology for drug development – where do industry interests lie?
  • Challenges in rare disease trials in immunology
  • Case Study – Sarepta’s Elevidys in Duchenne Muscular Dystrophy (DMD)